C-CAR088

N/A

Report date: 2026/02/12 20:00:14

Base Information

Drug NameC-CAR088
Drug Alias NameAnti BCMA CAR T Cell TherapyC-CAR088
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-cell maturation protein inhibitors
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCellular Biomedicine (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCellular Biomedicine Group LtdInstitute Of Hematology & Blood Diseases HospitalShanghai Cellular Biopharmaceutical Group Ltd +[4] 
Inactive CompaniesThe First Affiliated Hospital With Nanjing Medical UniversityHebei Yanda Ludaopei Hospital
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A